352 related articles for article (PubMed ID: 37377896)
1. Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans.
Oh W; Kim AMJ; Dhawan D; Kirkham PM; Ostafe R; Franco J; Aryal UK; Carnahan RH; Patsekin V; Robinson JP; Knapp DW; Lim SO
Cancer Res Commun; 2023 May; 3(5):860-873. PubMed ID: 37377896
[TBL] [Abstract][Full Text] [Related]
2. Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
Yoshimoto S; Chester N; Xiong A; Radaelli E; Wang H; Brillantes M; Gulendran G; Glassman P; Siegel DL; Mason NJ
MAbs; 2023; 15(1):2287250. PubMed ID: 38047502
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry
Sirivisoot S; Boonkrai C; Wongtangprasert T; Phakham T; Muanwein P; Pisitkun T; Sawangmake C; Radtanakatikanon A; Rungsipipat A
Vet Q; 2023 Dec; 43(1):1-9. PubMed ID: 37477617
[TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
5. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Ma W; Gilligan BM; Yuan J; Li T
J Hematol Oncol; 2016 May; 9(1):47. PubMed ID: 27234522
[TBL] [Abstract][Full Text] [Related]
6. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M; Huang Q; Xie Y; Wu X; Ma H; Zhang Y; Xia Y
J Hematol Oncol; 2022 Mar; 15(1):24. PubMed ID: 35279217
[TBL] [Abstract][Full Text] [Related]
7. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B
Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322
[TBL] [Abstract][Full Text] [Related]
9. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
10. Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site.
Wang X; Li X; Ito A; Sogo Y; Ohno T
Acta Biomater; 2022 Jun; 145():235-245. PubMed ID: 35398544
[TBL] [Abstract][Full Text] [Related]
11. A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Rubio-Pérez L; Lázaro-Gorines R; Harwood SL; Compte M; Navarro R; Tapia-Galisteo A; Bonet J; Blanco B; Lykkemark S; Ramírez-Fernández Á; Ferreras-Gutiérrez M; Domínguez-Alonso C; Díez-Alonso L; Segura-Tudela A; Hangiu O; Erce-Llamazares A; Blanco FJ; Santos C; Rodríguez-Peralto JL; Sanz L; Álvarez-Vallina L
Oncoimmunology; 2023; 12(1):2205336. PubMed ID: 37114242
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Li Q; Han J; Yang Y; Chen Y
Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
[TBL] [Abstract][Full Text] [Related]
13. Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development.
Phakham T; Boonkrai C; Wongtangprasert T; Audomsun T; Attakitbancha C; Saelao P; Muanwien P; Sooksai S; Hirankarn N; Pisitkun T
Sci Rep; 2022 Oct; 12(1):17792. PubMed ID: 36273231
[TBL] [Abstract][Full Text] [Related]
14. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
[TBL] [Abstract][Full Text] [Related]
15. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
Li K; Tian H
J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
[TBL] [Abstract][Full Text] [Related]
16. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
17. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S
Front Immunol; 2021; 12():619209. PubMed ID: 33790893
[TBL] [Abstract][Full Text] [Related]
18. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
[TBL] [Abstract][Full Text] [Related]
19. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
[No Abstract] [Full Text] [Related]
20. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]